Skip to the reporting
My account Sign in Subscribe
2 of 3 free articles left this month Subscribe now
← Funding
Funding Funding

Isomorphic Labs raises $5bn as Hassabis’s drug-design venture prepares for its first human trials

The London company, which has yet to test a drug of its own on a patient, has now raised about $7.7bn from outside investors in 20 months, with…

By Zack Hill November 18, 2026 · 3 min read
Share Share on X Share on LinkedIn Share on Facebook Share on WhatsApp Email this

The London company, which has yet to test a drug of its own on a patient, has now raised about $7.7bn from outside investors in 20 months, with the UK government’s Sovereign AI Fund among them.

Isomorphic Labs, the London drug discovery company led by the Nobel laureate Sir Demis Hassabis, has raised $5bn (£3.8bn) in a Series C round.It was described  as one of the largest funding rounds in British technology. The round was announced on Tuesday and co-led by the American investors Greenoaks and Sequoia Capital. The company said it was oversubscribed.

Isomorphic did not disclose a valuation. On 4 November Bloomberg reported, citing people familiar with the talks, that the round would value the company at about $50bn. City AM put the company’s earlier valuation at roughly $17.5bn. The company has not confirmed either figure. The size of the bet stands out because Isomorphic has not yet tested any of its own drug candidates in humans.

Andreessen Horowitz joined as a new investor. Alphabet, Google’s parent company and Isomorphic’s original owner, put in more money. So did every existing backer: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The round comes six months after a $2.1bn Series B led by Thrive and 20 months after Isomorphic’s first outside round of $600m in March 2025. Together, the three rounds bring its disclosed outside funding to about $7.7bn.

“Our drug design engine is generating molecules with unprecedented precision and speed,” Sir Demis said. Kanishka Narayan, the UK’s AI minister, called it “one of the biggest Series C rounds in UK tech history.” He said he was proud the government fund had invested again. The £500m Sovereign AI Fund first bought into Isomorphic in May, soon after the venture capitalist Suzanne Ashman became its managing partner.

Sir Demis co-founded DeepMind in 2010 and sold it to Google in 2014 for a reported £400m. He still runs Google DeepMind. Isomorphic was spun out in 2021 to turn the science behind AlphaFold into medicines. AlphaFold is DeepMind’s system for predicting the three-dimensional shapes of proteins. That work won Sir Demis and his colleague John Jumper a share of the 2024 Nobel Prize in Chemistry, which they split with the American biochemist David Baker. AlphaFold 3, released in 2024 with Isomorphic, goes further: it predicts how proteins interact with DNA, RNA and the small molecules that make up most medicines.

The commercial case rests on how often drug development fails. A widely cited industry estimate holds that about nine in ten candidates that enter clinical trials never win approval, and development commonly takes more than a decade. Isomorphic argues that computer models can predict how a molecule will bind to a disease target, and how it will behave, accurately enough to rule out weak candidates before chemists make them. Its platform, called IsoDDE, combines models that predict molecular behaviour with models that generate new molecules.

Big drugmakers have signed up. In 2024 Isomorphic made deals with Eli Lilly and Novartis that could together be worth nearly $3bn, not counting royalties. It also works with Johnson & Johnson. Its own programmes focus on cancer and immune disorders. The company says it has positive preclinical results in oncology and immunology, from both its own projects and its partners’, which it says prepare the way for clinical trials.

The company has not met its own deadlines so far. In 2025 Sir Demis said AI-designed drugs would be in clinical trials by the end of that year. At Davos in January, Reuters reported, he moved the target to the end of 2026. He later told Bloomberg he had “misspoken” and had meant preclinical studies. Tuesday’s announcement gave no start date for trials, and about six weeks of 2026 remain.

Isomorphic says the new money will go into its simulation models, research into new areas of biology, and the systems it needs to move candidates into clinical trials. The company has offices in London, Cambridge, Massachusetts and Lausanne.

Competition for this kind of capital is growing, but rival valuations remain far lower. Chai Discovery, a rival developer of AI drug-design models, recently raised $400m at a valuation of $3.8bn, according to Tech Funding News. Isomorphic’s lead investors are betting that its link to DeepMind and its partnerships with drugmakers justify a much higher price. Data from its first human trial, whenever it starts, will be the first evidence from patients on whether that bet is sound.

 

 

The Daily Briefing
One email, 7am, the six things that moved

Written by the newsroom, not a summariser. Free, and you can leave whenever.

0 comments

Anyone can read the thread · subscribers can post
Subscriber conversation Read the thread below as long as you like. Posting is open to subscribers, which is why it reads like a newsroom and not a comment section. Join the conversation Sign in
Sponsored Paid for by the advertiser. The newsroom had no part in it.

More on this topic

All Funding →